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1715-41 Thrombolytic Therapy During the "Golden Rrst Hour"
in GUSTO
The cost of hospitalization was significantly greater in pts with recurrent
ischemia ($21,069vs. $17,492, p = 0.02) or reinfarction ($22.772 vs. $17,721,
p = 0.06) compared with patients without these complications.
Thus; These findings suggest that a strategy of prophylactic IASP therapy
after patency has been established during acute myocardial infarction while
improving clinical outcomes does not increase hospitalization cost.
2:30
1715-3 [ Cost Implications of Aortic Counterpulsation in Acute
Myocardial Infarction: Results from a Randomized
Clinical Trial
J. David Talley. E. Magnus Ohman. Barry S. George. Morton J. Kern. Christopher
J. White. Conor Lundergan. Joseph R. Hartmann. Paul A. Gurbel. Harry R. Phillips.
Lisa G. Berdan. Lai Choi Lam. Robert M. Califf. Daniel B. Mark. University of
Arkansas. Uttle Rock. AR; Duke University, Durham. NC
To evaluate the cost implications of prophylactic aortic counterpulsation
(IASP) to sustain coronary artery patency during acute myocardial infarction.
we evaluated 102 (55%) from the 182 patients enrolled in the randomized
IABP study. After coronary artery patency was established during acute car-
diac catheterization. pts were randomized to IABP (N = 52) for 48 hours ver-
sus standard therapy. Control (C) = 50. During the hospitalization. pts with
IASP had less recurrent ischemia (4% vs. 21 %). less reinfarction (3% vs. 8%1.
less reocclusion (8% vs. 21 %). and less need for emergency PTCA (2% vs.
11 %). The duration of hospitalization (IASP = 104vs. C = 9.7 daysl and CCU
stay (IABP = 4.7 vs. C = 3.9 days) were similar. The outcomes were similar
in the sUbstudy compared with the overall clinical trial. Median costs were:
9% lower among the first hour pts (and not different between t-PA and SK
groups) than among those treated later, comparable to the overall 14% mor-
tality reduction by t-PA compared with SK in the main trial. Thus, despite
the apparent existence of a "golden first hour" during early reperfusion tri-
als, outcome following thrombolysis during the first hour in GUSTO was only
modestly better than among patients treated later.
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1715-51 Reteplase vs Alteplase Patency Investigation During
Myocardial Infarction Trial (RAPID 2)
W. Douglas Weaver. Christoph Bode, Curtis Burnett, John Kalbfleisch,
Gerald Lorch, Semi Sen, Robert Chernoff, Richard Smalling. RAPID 2 Trial
Investigators. University of Washington, Seattle. WA
It has been previously shown that double-bolus reteplase (r-PA) resulted in
superior TIMI 3 flow rates at 60 and 90 minutes and follow-up compared
to "standard" dose (100 mg/3 hours) alteplase (t-PA). To test whether this
regimen was also superior to "accelerated" (100 mg/90 minutes) dose t-PA
we studied 320 patients with acute myocardial infarction (MI). Patients were
randomized to receive either 10 + 10 mu (30 minutes apart) bolus doses of r-
PA or a 90-minute "accelerated" dose of t-PA. All patients received aspirin and
IV heparin. Patency and TIMI3 flow rates were determined at 30,60, and 90
minutes and prior to discharge. The trial was completed 1 September 1994.
A preliminary analysis of the baseline characteristics in the first 164 patients
showed the average age was 58.4 years, 79% were male, 52% were current
smokers. 9% had a prior history of MI. 43% had hypertension. and 25% had
prior angina. The median time to treatment was 2.2 hours (25-75%tiles, 1.6-
3.8 hours). The infarct related artery was the anterior descending in 36%. the
right coronary in 52%. and the circumflex artery in 11 % of patients.
In the combined data from both treatment groups, there were 14 deaths
(8.6%). 4 strokes (2.4%). and 15.9% had "rescue" PTCA at 90 minutes be-
cause of continued coronary occlusion.
A complete comparative analysis of the angiographic and clinical findings
in the r-PA and "accelerated" t-PA treatment groups will be presented.
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Non-ICU $
1.804
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IABP
Control
<1 hr 1-6 hr <1 hr 1-6 hr
Age (yrsl 60.1 60.9 Killip 3 or 4 (%) 21 2.0
Male(%) 78.8 74.8 Systolic BP (mm) 127 129
Prior Angina (%) 46.4 36.5 Pulse (bpm) 75 75
Prior MI (%) 20.7 16.1 Anterior MI (%) 43 39
A. Michael Lincoff. Robert M. Califf, Wolfgang Rutsch. Amanda Stebbins. Eric
J. Topol. GUSTO Investigators. Cleveland Clinic Foundation. Cleveland. OH
Data derived from thrombolytic trials performed during the placebo-
controlled era have suggested that initiation of reperfusion therapy during
the "golden first hour" after onset of infarction may dramatically reduce mor-
tality and improve myocardial salvage. Pts presenting within 1 hr in these
early studies may also have differed from those presenting later by hav-
ing larger infarctions or more hemodynamic compromise; early therapy may
thus compensate for the high-risk profile of these patients. To determine in
a large contemporary cohort the extent to which early-treated pts differ with
regard to baseline characteristics and clinical outcome from pts presenting
later, 1269 pts (3.2% of total) randomized to 4 different thrombolytic regi-
mens within 1 hr of symptom onset (mean 0.8 ± 0.2 hr) were compared
with 38,562 pts treated between 1 and 6 hrs (mean 3.2 ± 1.6 hr) in GUSTO.
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!715-6!lnternational Joint Efficacy Comparison of
Thrombolytics (INJECT): Reteplase vs Streptokinase
in Acute Myocardial Infarction
John Hampton, Wolfgang Meyer-Sabellek. Rolf Schroder. Robert Wilcox. INJECT
Trial Study Group. University of Nottingham, UK; Universitiitsklinikum Benjamin
Franklin, Berlin, Germany
Reteplase (r-PA) is a non-glycosylated recombinant plasminogen activator
containing the kringle-2 and protease domains but lacking the finger, epi-
dermal growth factor and kringle-1 domains. It has a longer half-life than
native t-PA and the 20 MU dose administered as two 10 MU boluses sepa-
rated by 30 minutes has been shown to achieve a 90 minute patency rate
of 85%. The objective of the INJECT trial was to compare the efficacy and
safety of this r-PA regimen with standard regimen Streptokinase (1.5 M U over
60 minutes) in patients with acute myocardial infarction receiving treatment
within 12 hours of symptom onset. A double-blind. double-dummy design
was employed and standard inclusion/exclusion criteria for thrombolysis ap-
plied. The primary endpoint was 35 day survival. Target recruitment was 6000
patients, this number providing good power to determine the clinical benefit
of r-PA. Total recruitment was achieved over one year to September 1994.
211 Coronary Care Units in 9 countries participated. This paper will present
for the first time the results of INJECT and thus provide a detailed character-
isation of the efficacy and safety (including mortality) of Reteplase, a second
generation direct plasminogen activator.
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Mortality (30-Day) Death + Stroke
Pts receiving thrombolysis early «1 hr) in the course of MI did not differ
substantially with regard to severity of MI or any baseline clinical parameter
from those presenting 1-6 hrs after symptom onset, except for a trend to-
ward more frequent prior angina in the <1 hr group. Mortality (30-dayl was
Silent Myocardial Ischemia
Monday, March 20,1995,2:00 p.m.-3:30 p.m.
Ernest N. Morial Convention Center, Room 61
2:00
\716-1 I Long-term Prognostic Significance of
Exercise-Induced Silent Myocardial Ischemia in
Apparently Healthy Volunteers
Jerome L. Fleg. Alan B. Zonderman. Lewis C. Becker, Steven P. Schulman,
Gary Gerstenblith, Edward G. Lakatta. Gerontology Research Center. NlA, NIH. and
Johns Hopkins Bayview Medical Center. Baltimore. MD
Silent myocardial ischemia (SI) defined by concordant ST segment depres-
